Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Transfer of few immune cells can protect immunodeficient patients

Transfer of few immune cells can protect immunodeficient patients

Lipids efficiently kill leukemia cells

Lipids efficiently kill leukemia cells

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

Paradigm shift in new, highly targeted leukaemia therapy

Paradigm shift in new, highly targeted leukaemia therapy

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Protein may be key to maintaining health of aging blood stem cells

Protein may be key to maintaining health of aging blood stem cells

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Research roundup: Funding for safety-net hospitals; insurance competition

Research roundup: Funding for safety-net hospitals; insurance competition

Gene variants that lead to longer telomeres boost brain cancer risk

Gene variants that lead to longer telomeres boost brain cancer risk

NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

NCCN ORP awards six grants to improve care for patients with renal or hematologic malignancies

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

Researchers reproduce tumor chromosomal translocations in human cells

Researchers reproduce tumor chromosomal translocations in human cells

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

Nonadherence triples relapse risk in African American and Asian children in remission from ALL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.